Reference Susceptibility Testing and Genomic Surveillance of Clostridioides difficile, United States, 2012-17

被引:15
|
作者
Gargis, Amy S. [1 ]
Karlsson, Maria [1 ,2 ]
Paulick, Ashley L. [1 ]
Anderson, Karen F. [1 ]
Adamczyk, Michelle [1 ]
Vlachos, Nicholas [1 ]
Kent, Alyssa G. [1 ]
McAllister, Gillian A. [1 ]
McKay, Susannah L. [1 ]
Halpin, Alison L. [1 ]
Albrecht, Valerie [1 ]
Campbell, Davina [1 ]
Korhonen, Lauren [1 ]
Elkins, Christopher A. [1 ]
Rasheed, J. Kamile [1 ]
Guh, Alice Y. [1 ]
McDonald, L. Clifford [1 ]
Lutgring, Joseph D. [1 ]
机构
[1] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA
[2] Goldbelt C6 LLC, Chesapeake, VA USA
关键词
Clostridioides difficile; antibiotic resistance; vancomycin; metronidazole; agar dilution; ANTIMICROBIAL SUSCEPTIBILITY; RESISTANCE; INFECTION; CARE; EMERGENCE; EPIDEMIC;
D O I
10.1093/cid/ciac817
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Reference susceptibility testing revealed that elevated minimum inhibitory concentrations (MICs) to vancomycin and metronidazole were rare among US Clostridioides difficile isolates. Ribotype 027 was associated with increased MICs to several antibiotics including fluoroquinolones and clindamycin. Background Antimicrobial susceptibility testing (AST) is not routinely performed for Clostridioides difficile and data evaluating minimum inhibitory concentrations (MICs) are limited. We performed AST and whole genome sequencing (WGS) for 593 C. difficile isolates collected between 2012 and 2017 through the Centers for Disease Control and Prevention's Emerging Infections Program. Methods MICs to 6 antimicrobial agents (ceftriaxone, clindamycin, meropenem, metronidazole, moxifloxacin, and vancomycin) were determined using the reference agar dilution method according to Clinical and Laboratory Standards Institute guidelines. Whole genome sequencing was performed on all isolates to detect the presence of genes or mutations previously associated with resistance. Results Among all isolates, 98.5% displayed a vancomycin MIC <= 2 mu g/mL and 97.3% displayed a metronidazole MIC <= 2 mu g/mL. Ribotype 027 (RT027) isolates displayed higher vancomycin MICs (MIC50: 2 mu g/mL; MIC90: 2 mu g/mL) than non-RT027 isolates (MIC50: 0.5 mu g/mL; MIC90: 1 mu g/mL) (P < .01). No vanA/B genes were detected. RT027 isolates also showed higher MICs to clindamycin and moxifloxacin and were more likely to harbor associated resistance genes or mutations. Conclusions Elevated MICs to antibiotics used for treatment of C. difficile infection were rare, and there was no increase in MICs over time. The lack of vanA/B genes or mutations consistently associated with elevated vancomycin MICs suggests there are multifactorial mechanisms of resistance. Ongoing surveillance of C. difficile using reference AST and WGS to monitor MIC trends and the presence of antibiotic resistance mechanisms is essential.
引用
收藏
页码:890 / 896
页数:7
相关论文
共 50 条
  • [1] Surveillance of Clostridioides difficile Antimicrobial Resistance in the United States
    Gonzales-Luna, Anne J.
    Dureja, Chetna
    Eubank, Taryn A.
    Garey, Kevin W.
    Hurdle, Julian G.
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (11) : 2038 - 2039
  • [2] Genomic surveillance of Clostridioides difficile transmission and virulence in a healthcare setting
    Newcomer, Erin P.
    Fishbein, Skye R. S.
    Zhang, Kailun
    Hink, Tiffany
    Reske, Kimberly A.
    Cass, Candice
    Iqbal, Zainab H.
    Struttmann, Emily L.
    Burnham, Carey-Ann D.
    Dubberke, Erik R.
    Dantas, Gautam
    MBIO, 2024, 15 (03):
  • [3] Genomic Analysis of Clostridioides difficile in 2 Regions of the United States Reveals a Diversity of Strains and Limited Transmission
    Pecora, Nicole
    Holzbauer, Stacy
    Wang, Xiong
    Gu, Yu
    Taffner, Samantha
    Hatwar, Trupti
    Hardy, Dwight
    Dziejman, Michelle
    D'Heilly, Paige
    Pung, Kelly
    Guh, Alice
    Qiu, Xing
    Gill, Steven
    Dumyati, Ghinwa
    JOURNAL OF INFECTIOUS DISEASES, 2022, 225 (01): : 121 - 129
  • [4] Preferences for a Clostridioides difficile vaccine among adults in the United States
    Vietri, Jeffrey
    Maculaitis, Martine C.
    Cappelleri, Joseph C.
    Yu, Holly
    Kopenhafer, Lewis
    Beusterien, Kathleen
    VACCINE, 2024, 42 (24)
  • [5] Longitudinal genomic surveillance of carriage and transmission of Clostridioides difficile in an intensive care unit
    Miles-Jay, Arianna
    Snitkin, Evan S.
    Lin, Michael Y.
    Shimasaki, Teppei
    Schoeny, Michael
    Fukuda, Christine
    Dangana, Thelma
    Moore, Nicholas
    Sansom, Sarah E.
    Yelin, Rachel D.
    Bell, Pamela
    Rao, Krishna
    Keidan, Micah
    Standke, Alexandra
    Bassis, Christine
    Hayden, Mary K.
    Young, Vincent B.
    NATURE MEDICINE, 2023, 29 (10) : 2526 - +
  • [6] Longitudinal genomic surveillance of carriage and transmission of Clostridioides difficile in an intensive care unit
    Arianna Miles-Jay
    Evan S. Snitkin
    Michael Y. Lin
    Teppei Shimasaki
    Michael Schoeny
    Christine Fukuda
    Thelma Dangana
    Nicholas Moore
    Sarah E. Sansom
    Rachel D. Yelin
    Pamela Bell
    Krishna Rao
    Micah Keidan
    Alexandra Standke
    Christine Bassis
    Mary K. Hayden
    Vincent B. Young
    Nature Medicine, 2023, 29 : 2526 - 2534
  • [7] Malaria Surveillance - United States, 2012
    Cullen, Karen A.
    Arguin, Paul M.
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2014, 63 (12): : 1 - 22
  • [8] Malaria Surveillance - United States, 2012
    Cullen, Karen A.
    Arguin, Paul M.
    MMWR SURVEILLANCE SUMMARIES, 2014, 63 (12): : 1 - 26
  • [9] Abortion Surveillance United States, 2012
    Pazol, Karen
    Creanga, Andreea A.
    Jamieson, Denise J.
    MMWR SURVEILLANCE SUMMARIES, 2015, 64 (10): : 1 - 40
  • [10] A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020-2021
    Snydman, D. R.
    Mcdermott, L. A.
    Thorpe, C. M.
    Goldstein, E. J. C.
    Schuetz, A. N.
    Johnson, S.
    Gerding, D. N.
    Gluck, L.
    Bourdas, D.
    Carroll, K. C.
    Lancaster, C. K.
    Garey, K. W.
    Wang, Q.
    Walk, S. T.
    Duperchy, E.
    Silverman, Jared A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (10)